{"denoms":[{"counts":[{"groupId":"BG000","value":"407"},{"groupId":"BG001","value":"403"},{"groupId":"BG002","value":"810"}],"units":"Participants"}],"groups":[{"description":"Fludarabine+cyclophosphamide (FC) intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/m² IV on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/m² IV on Days 1, 2, 3 for 6 cycles.","id":"BG000","title":"Fludarabine+Cyclophosphamide (FC)"},{"description":"Rituximab intravenously for a total of 6 treatment cycles at intervals of 28 days. Cycle 1: 375 mg/m² IV on Day 0; Cycles 2-6: 500 mg/m² IV on Day 1. FC intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/m² IV over 15-30 min on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/m² IV over 15-30 min on Days 1, 2, 3 for 6 cycles.","id":"BG001","title":"Fludarabine+Cyclophosphamide+Rituximab (FCR)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.55","value":"59.3"},{"groupId":"BG001","spread":"8.70","value":"59.6"},{"groupId":"BG002","spread":"8.62","value":"59.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"105"},{"groupId":"BG001","value":"105"},{"groupId":"BG002","value":"210"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"302"},{"groupId":"BG001","value":"298"},{"groupId":"BG002","value":"600"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}